Is Immunovia AB (publ) (IMMVF) a Buy, Sell, or Hold?
Immunovia AB (publ)
PNK:IMMVF
$0.07382 USD
-$2.93 (-97.54%)
- Volume
- 325
- Average Volume
- 0
- Market Capitalization
- $4.97M
- P/E Ratio
- -0.33
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $0.17
- Year Low
- $0.07
- Payout Ratio
- $0.00
- Current Ratio
- $1.10
Industry, Sector & symbol
| Stock Exchange | Other OTC |
| CEO | Mr. Jeff Borcherding |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | IMMVF |
| CUSIP | None |
| CIK | None |
| Web | https://www.immunovia.com |
| Phone | 46 4 62 75 60 00 |
| Currency | USD |
| Employees | 11 |
| Country | SE |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.10 |
| Quick Ratio | 1.10 |
| Cash Ratio | 0.95 |
Sales & Book Value
| Annual Sales | $1.58M |
| Price / Sales | 125.03 |
| Cash Flow | -2.57 |
| Price / Cash Flow | -0.96 |
| Price / Book | 1.93 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | |
| Rating Score(0-5) | |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-7.95 |
| Trailing P/E Ratio | -0.33 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | $-309.44M |
| Net Margin | -13120.79% |
| Pretax Margin | -13120.79% |
| Return on Equity | -207.71% |
| Return on Assets | -199.28% |
Financials Score
| AltmanZ Score | -32.57 |
| Piotroski Score | 3.00 |
| Working Capital | 3.8M |
| Total Assets | 58.27M |
| Ebit | -116.77M |
| Market Cap | 4.97M |
| Total Liabilities | 38.56M |
Poll Results
About Immunovia AB (publ) (PNK:IMMVF) Stock
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden. ...
2024-11-07 09:22:00
SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration of 51 pancreatic centers worldwide conducting unprecedented research for the early detection of pancreatic cancer in individuals with increased risk for the disease. Immunovia will share results from studies of its next-generation test to detect stage 1 and 2 pancreatic cancer, including the discovery study, model-development study, and analytical validation.
2024-09-16 12:16:00
LUND, Sweden , Sept. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer (abstract #B027).
Immunovia announces updated financial calendar
2024-03-12 10:29:00
LUND, Sweden , March 12, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq) (IMMNOV: Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, updates its financial calendar for 2024. Annual Report to be published April 25, 2024 Q1 Report, 2024 April 25, 2024 Annual General Meeting June 4, 2024 Q2 Report, 2024 August 22, 2024 Q3 Report, 2024 November 14, 2024 For more information, please contact: Karin Almqvist LiwendahlChief Financial Officer [email protected] +46 709 11 56 08 Immunovia in brief Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection.
2023-07-12 03:12:00
LUND, Sweden , July 12, 2023 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, today announced plans to restructure its operations. The company will cease commercialization of its IMMray PanCan-d test in the United States to focus its resources on the further development and clinical testing of the Company's promising next generation pancreatic cancer detection test.
Immunovia to present at Gilmartin Group's Emerging Growth Company Showcase
2022-08-23 02:49:00
LUND, Sweden , Aug. 23, 2022 /PRNewswire/ -- Immunovia today announced it will participate in Gilmartin Group's Emerging Growth Company Showcase on August 31, 2022. Philipp Mathieu, CEO and President, and Jeff Borcherding, US CEO, are scheduled to present on Wednesday, August 31, 2022 at 9:00 am ET (15:00 pm CET).
Frequently Asked Questions
-
What is the current Immunovia AB (publ) (IMMVF) stock price?
-
Immunovia AB (publ)(PNK:IMMVF) stock price is $0.07382 in the last trading session. During the trading session, IMMVF stock reached the peak price of $3.155 while $0.07382 was the lowest point it dropped to. The percentage change in IMMVF stock occurred in the recent session was --97.54% while the dollar amount for the price change in IMMVF stock was -$-2.93.
-
IMMVF's industry and sector of operation?
-
The PNK listed IMMVF is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of IMMVF?
-
Mr. Jeff Borcherding | Global Chief Executive Officer & President
Ms. Karin Almqvist Liwendahl | Chief Financial Officer
Ms. Lara E. Sucheston-Campbell | Head of Clinical & Medical Affairs
|
| -
How many employees does IMMVF have?
-
Number of IMMVF employees currently stands at 11. IMMVF operates from Medicon Village, Lund, None 223 63, SE.
-
Link for IMMVF official website?
-
Official Website of IMMVF is: https://www.immunovia.com
-
How do I contact IMMVF?
-
IMMVF could be contacted at phone #46 4 62 75 60 00 and can also be accessed through its website. IMMVF operates from Medicon Village, Lund, None 223 63, SE.
-
How many shares of IMMVF are traded daily?
-
The average number of IMMVF shares traded daily for last 3 months was 0.
-
What is the market cap of IMMVF currently?
-
The market value of IMMVF currently stands at $4.97M with its latest stock price at $0.07382